<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioatla Inc — News on 6ix</title>
<link>https://6ix.com/company/bioatla-inc</link>
<description>Latest news and press releases for Bioatla Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioatla-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354b6578dffbe2df0e513c.webp</url>
<title>Bioatla Inc</title>
<link>https://6ix.com/company/bioatla-inc</link>
</image>
<item>
<title>BioAtla Announces Share Consolidation</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announces-share-consolidation-4</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announces-share-consolidation-4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the</description>
</item>
<item>
<title>BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights-5</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights-5</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March</description>
</item>
<item>
<title>BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-assets</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-assets</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partner</description>
</item>
<item>
<title>BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-gatc-health-announce-40-120000417</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-gatc-health-announce-40-120000417</guid>
<pubDate>Wed, 31 Dec 2025 12:00:00 GMT</pubDate>
<description>BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.Oz-V targets ROR2, an importa</description>
</item>
<item>
<title>BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-enters-agreements-22-5-052500740</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-enters-agreements-22-5-052500740</guid>
<pubDate>Fri, 21 Nov 2025 05:25:00 GMT</pubDate>
<description>These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year endThese agreements ensure BioAtla can maintain operational momentum while completing that process SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company</description>
</item>
<item>
<title>BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-reports-third-quarter-2025-210500706</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-reports-third-quarter-2025-210500706</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in th</description>
</item>
<item>
<title>BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-mecbotamab-vedotin-mec-v-140000286</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-mecbotamab-vedotin-mec-v-140000286</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinic</description>
</item>
<item>
<title>BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announce-third-quarter-2025-130000619</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announce-third-quarter-2025-130000619</guid>
<pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference Call and Webcast</description>
</item>
<item>
<title>BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-presents-compelling-mechanistic-rationale-120000884</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-presents-compelling-mechanistic-rationale-120000884</guid>
<pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma” which details clin</description>
</item>
<item>
<title>BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-presents-promising-interim-data-from-its-phase-1-trial-with-ba3182-in-patients-with-treatment-refractory-metastatic-adenocarcinoma-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-presents-promising-interim-data-from-its-phase-1-trial-with-ba3182-in-patients-with-treatment-refractory-metastatic-adenocarcinoma-at-esmo-2025</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses</description>
</item>
<item>
<title>BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-present-clinical-data-mecbotamab-130000757</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-present-clinical-data-mecbotamab-130000757</guid>
<pubDate>Fri, 03 Oct 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual</description>
</item>
<item>
<title>BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announces-regulatory-clinical-development-120000657</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announces-regulatory-clinical-development-120000657</guid>
<pubDate>Mon, 08 Sep 2025 12:00:00 GMT</pubDate>
<description>FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCA</description>
</item>
<item>
<title>BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-reports-second-quarter-2025-200500021</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-reports-second-quarter-2025-200500021</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to</description>
</item>
<item>
<title>BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announce-second-quarter-2025-120000580</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announce-second-quarter-2025-120000580</guid>
<pubDate>Mon, 04 Aug 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and Webcast Informa</description>
</item>
<item>
<title>BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-announces-upcoming-oral-presentation-120000364</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-announces-upcoming-oral-presentation-120000364</guid>
<pubDate>Thu, 17 Jul 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced an oral presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting to be held in Hong Kong Sar, China from July 18–20, 2025. Oral Presentation Details: Title: First-in-human</description>
</item>
<item>
<title>BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-presents-data-ongoing-dose-120000136</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-presents-data-ongoing-dose-120000136</guid>
<pubDate>Thu, 03 Jul 2025 12:00:00 GMT</pubDate>
<description>Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody</description>
</item>
<item>
<title>BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Ga...</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally-binding-epcam-x-cd3-bispecific-t-cell-engager-in-patients-with-treatment-refractory-metastatic-adenocarcinoma-at-the-2025-european-society-for-medical-oncology-esmo-ga</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally-binding-epcam-x-cd3-bispecific-t-cell-engager-in-patients-with-treatment-refractory-metastatic-adenocarcinoma-at-the-2025-european-society-for-medical-oncology-esmo-ga</guid>
<pubDate>Thu, 03 Jul 2025 04:00:00 GMT</pubDate>
<description>BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment</description>
</item>
<item>
<title>BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-presents-phase-2-ozuriftamab-120000122</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-presents-phase-2-ozuriftamab-120000122</guid>
<pubDate>Mon, 02 Jun 2025 12:00:00 GMT</pubDate>
<description>45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stag</description>
</item>
<item>
<title>BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-reports-first-quarter-2025-200500794</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-reports-first-quarter-2025-200500794</guid>
<pubDate>Tue, 06 May 2025 20:05:00 GMT</pubDate>
<description>CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agent</description>
</item>
<item>
<title>BioAtla to Participate in the Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/bioatla-inc/news/bioatla-participate-citizens-life-sciences-120000548</link>
<guid isPermaLink="true">https://6ix.com/company/bioatla-inc/news/bioatla-participate-citizens-life-sciences-120000548</guid>
<pubDate>Wed, 30 Apr 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one inves</description>
</item>
</channel>
</rss>